Latest news with #LalPathlabs
Business Standard
7 days ago
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
Time of India
21-06-2025
- Health
- Time of India
Delhi consumer panel upholds verdict indicting Dr Lal Pathlabs for wrong report
New Delhi: The Delhi State Consumer Disputes Redressal Commission has upheld a finding on Dr Lal Pathlabs being deficient in service and ordering it pay compensation to a patient over a wrong lab report . The state consumer commission's president Sangita Dhingra Sehgal and judicial member Pinki were hearing the lab's appeal against the August 2014 order of a district forum indicting the lab for a wrong test report and ordering Rs 3.5 lakh compensation. In its order on May 26, the commission said, "When a patient's urea levels are reported at more than ten times the normal range, triggering emergency hospitalisation and profound distress, the laboratory cannot retreat behind semantic arguments about its limited role in the diagnostic chain. Moreover, the appellant's (Lal Pathlabs) attempt to shift blame onto prescribing physicians or the Respondent's medical history holds no ground." It said if the tests carried out by a laboratory are defective and erroneous, the diagnosis by a doctor will be incorrect, resulting in improper treatment and the "medicines prescribed based on a wrong test report and diagnosis may lead to fatal results for the patient". "When multiple test reports from different laboratories show consistent results that differ significantly from one laboratory's findings, it creates a strong presumption of deficiency in service by the outlier laboratory," the commission added. Rejecting the lab's argument that the results were due to a particular drug consumed by the complainant, the commission said, "Even if it is assumed that the respondent (complainant) was taking Spirex tablets, we find it implausible that there could be such astronomical difference in patient's test reports pertaining to creatine and urea." It also rejected the lab's argument that the complainant did not agree to their request for re-collecting the sample, saying the report depicted the values of various important health indicators to be so high that any person having ordinary prudence would be perturbed by such results. "The respondent was under no obligation to get the tests redone. He got another test done from 3 labs, viz. Max Health Care, Dr Dangs Laboratory and Super Religare Laboratories Ltd, all of which depicted his parameters to be within the normal range," the commission said. The medical expenses incurred by the patient, in the panel's opinion, were directly attributable to the lab's erroneous report, which falsely indicated life-threatening conditions and necessitated emergency hospitalisation. The commission noted the discharge summary from Max Hospital "explicitly" linking the patient's admission there to the "erroneous outside lab report". "Being misdiagnosed with life-threatening conditions and undergoing unnecessary hospitalisation constitutes severe psychological trauma. The mental agony and physical suffering cannot be understated." The panel found the direction for compensation "just and reasonable". "We concur with the district commission's finding that the appellant failed to maintain the standard of reasonable care expected in pathological testing, thus amounting to a deficiency in service," it held.
Time of India
20-06-2025
- Health
- Time of India
Delhi consumer commission holds lab liable for faulty test report that led to hospitalisation
New Delhi: A faulty lab test report that triggers panic and emergency hospitalisation amounts to a deficiency in service, Delhi State Consumer Disputes Redressal Commission (DSCDRC) has said, asking a private pathology laboratory to compensate the affected customer. In a recent ruling, the state commission upheld the findings of a district consumer forum against Dr Lal Pathlabs and observed that its "grossly erroneous results constitute a failure to perform basic testing accurately, causing undue distress and unnecessary hospitalisation." Dismissing the appeal filed by the lab, the bench of Justice Sangita Dhingra Sehgal (president) and Pinki (member judicial) noted that if "the tests carried out by a laboratory are defective and erroneous, then the diagnosis by the doctor will not be correct, and the patient will not get the proper treatment. The medicines prescribed based on a wrong test report and diagnosis may lead to fatal results for the patient. When a patient's urea levels are reported at more than ten times the normal range, triggering emergency hospitalisation and profound distress, the laboratory cannot retreat behind semantic arguments about its limited role in the diagnostic chain." According to the complainant, on receiving the test report showing abnormally high creatinine levels at 8.39 mg/dl and urea at 189 mg/dl, while the reference range of creatinine is 0.6-1.3 mg/dl and urea at 6-21 mg/dl, the treating doctor directed immediate hospitalisation and further tests while preparing for a procedure. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 임플란트 29만원 이벤트 임플란트 더 알아보기 Undo However, further tests within 24-48 hours revealed normal readings. The same tests were conducted at two other private labs, which also showed the patient's parameters to be within the normal range. "It is to be noted that the medical expenses incurred by the respondent were directly attributable to the appellant's erroneous report, which falsely indicated life-threatening conditions and necessitated emergency hospitalisation ," the commission said. Rejecting the challenge to the award of Rs 3.5 lakh as compensation payable by the laboratory, the state commission pointed out that being "misdiagnosed with life-threatening conditions and undergoing unnecessary hospitalisation constitutes severe psychological trauma. The mental agony and physical suffering cannot be understated. Also, the prolonged litigation justifies litigation costs as a component of compensation. " Dr Lal Pathlabs said that there was no deficiency in service and that the tests were conducted under strict quality control protocols.
&w=3840&q=100)
Business Standard
25-04-2025
- Business
- Business Standard
Top Mid, smallcap stocks that rallied despite market fall today; check list
Stock market down today: Indian equity markets slipped into the red for a second consecutive session on Friday, April 25, as investor sentiment turned cautious amid rising geopolitical tensions between India and Pakistan, following a deadly terrorist attack in Jammu and Kashmir's Pahalgam, which claimed 26 lives. Investors suffered losses worth nearly ₹10 trillion during the day as the BSE Sensex and Nifty50 crashed over 1.5 per cent intraday. The 30-stock Sensex index touched a low of 78,606, while the 50-share Nifty hit 23,848. The broader markets fared worse, with the Nifty MidCap, and SmallCap indices dropping over 3 per cent each intraday. While majority stocks were nursing losses today, some names from the midcap and smallcap segments defied the weak market trend to record sharp gains. Among the midcap stocks, Coforge, Persistent Systems, Delhivery, GIC RE, KPIT Tech, JSW Infra, and Mphasis gained up to 3 per cent. Further, amog the smallcap stocks, at least 20 constituents of the Smallcap index were trading in green, rising up to 20 per cent. Among the top smallcap gainers today were Carraro India, Thyrocare Technologies, Repro India, Sterlite Technologies, Sasken Technologies, Goldiam International, Jubilant Ingrevia, and Nuvama Wealth Management. Here's why these stocks are rising today: Persistent Sytems: Shares of the technology services company surged over 3 per cent to hit intraday high of ₹5,330 on the BSE after it reported a 28 per cent Y-o-Y increase in net profit to ₹395.7 crore for the March 2025 quarter (Q4 FY25). The company's revenue grew 25.2 per cent Y-o-Y to ₹3,243 crore for Q4 FY25. In addition, the board recommended a final dividend of ₹15 per share. Analysts at Prabhudas Lilladher have upgraded Persistent Systems shares to 'Buy' from 'Accumulate', seeing decent upside in the stock from current levels. " Persistent Systems unique value proposition and its strong play around regulated verticals are keeping it more resilient in this adverse environment. Additionally, the investments around hiring senior leadership team within key verticals have been instrumental in fueling client mining/hunting activities and closing large strategic deals," the brokerage pointed out. It estimates US Dollar revenues/earnings CAGR of 17 per cent/24 per cent over FY25-FY27E. Mphasis: The pharma stock surged over 4 per cent to hit intraday high of ₹2,574.05 after the company reported 13.55 per cent Y-o-Y growth in net profit at 446.49 crore compared to ₹393.22 crore in the year-ago period. Net sales came in at ₹3,710.04 crore in Q4FY25, up 8.73 per cent from ₹3,412.05 crore in corresponding quarter previous fiscal. Dr Lal Pathlabs: Shares of the diagnostic and healthcare testing services company surged over 4 per cent to touch intraday high of ₹2,911 after reporting 83 per cent Y-o-Y increase in March 2025 quarter net profit to ₹154.80 crore. The company's revenue increased 10.5 per cent Y-o-Y to ₹602.60 crore.
